Energy-Based Devices for GLP-1 Receptor Agonist–Associated Facial Aging: A Tissue-Specific Safety Framework

Abstract

Glucagon-like peptide-1 receptor agonist (GLP-1RA)–associated rapid weight loss may be accompanied by facial changes resembling accelerated aging, colloquially termed “Ozempic face”. In this review, this proposed phenotype is termed GLP-1RA–associated facial accelerated aging (GLP-1RA-FAA) and is characterized primarily by facial volume loss and skin laxity, with possible but incompletely characterized alterations in dermal–adipose support, adipose-derived stem-cell biology, fibroblast–extracellular-matrix homeostasis, and facial muscle. Demand for energy-based device (EBD) treatment in this population is increasing; however, whether conventional EBD parameters are effective or safe in medication-associated facial volume depletion is unknown. A narrative review was informed by structured searches of PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library from January 2000 through August 31, 2026. Evidence was selected for clinical directness and relevance to radiofrequency, high-intensity focused ultrasound, broadband light, microwave, extracorporeal shock wave therapy, diode laser, and synchronized radiofrequency with high-intensity facial electrical stimulation. Available modalities differ in their intended tissue depth and in the potential relevance of three conceptual targets: preservation of adipose tissue, dermal fibroblast–extracellular-matrix remodeling, and facial muscle–SMAS support. Preclinical body-contouring studies suggest that sustained subcutaneous heating in the approximate 43–45°C range can be associated with adipocyte injury or apoptosis; however, no facial thermal dose threshold has been established, particularly in GLP-1RA-treated patients. No individual EBD modality has demonstrated simultaneous restoration of adipose, dermal, and muscle-related targets in prospective GLP-1RA-specific studies. Conservative control of treatment depth, careful avoidance of unnecessary deep energy deposition in volume-depleted regions, investigation of low-intensity dermal remodeling strategies, and evaluation of muscle-targeting approaches are proposed as research considerations. These concepts are hypothesis generating and do not constitute clinical recommendations or standards of care. Prospective controlled studies in well-characterized GLP-1RA-treated populations are required before device-specific protocols can be adopted.

Plain Language Summary

Medications used for weight management, including semaglutide (Ozempic^® and Wegovy^®) and tirzepatide (Mounjaro^® and Zepbound^®), can be associated with noticeable facial changes, particularly after substantial or rapid weight loss. These changes are often referred to informally in relation to specific medication brands, although they are not specific to one medication and may occur with medication-driven weight loss more broadly. Facial volume loss, looser skin, hollowing of the cheeks or temples, and a more tired or gaunt appearance may result mainly from loss of facial fat and other soft-tissue support. Whether these medications also affect the cells that maintain skin structure or facial muscles is still being studied. Energy-based devices are treatments that use controlled heat, light, ultrasound, or electrical stimulation. They are increasingly considered for skin tightening and facial rejuvenation. Different devices act at different tissue depths: some mainly affect the skin, whereas others may also reach deeper connective tissue, fat, or muscle. In people with medication-associated facial volume loss, deep or overly aggressive treatment may, in theory, affect already reduced fat layers or cause unwanted tissue injury. However, this possibility has not been adequately tested in people using GLP-1 receptor agonists or other weight-loss medications. This review examines the potential tissue targets, mechanisms, and available evidence for major energy-based technologies. It outlines cautious, research-oriented considerations, including careful control of treatment depth, conservative settings in thin or volume-depleted areas, and individualized assessment of whether muscle-targeting treatments may be appropriate. Direct clinical evidence in people with GLP-1RA-associated facial changes remains very limited. The approaches discussed in this review are early research considerations, not established treatment guidelines or standards of care.

Introduction

Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), and tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, are widely used pharmacotherapies for obesity and overweight. In pivotal trials, semaglutide 2.4 mg produced a mean body-weight reduction of approximately 14.9% at 68 weeks, whereas tirzepatide produced dose-dependent reductions of approximately 15.0% to 20.9% at 72 weeks by the treatment-regimen estimand.^1,2 Women constitute a substantial proportion of GLP-1RA users in weight-management cohorts, although sex and age distributions vary substantially by country, indication, healthcare setting, and data source.³ Substantial or rapid medication-driven weight loss has been associated with a facial phenotype popularized in lay media under brand-related terminology, which in this review is referred to as GLP-1RA–associated facial accelerated aging (GLP-1RA-FAA). Clinical features may include facial volume loss, skin laxity, hollowing, and a more skeletal or fatigued appearance.^4–6 A pharmacologically analogous mechanism of drug-induced accelerated skin aging has been described in androgen deprivation therapy.⁷ In a retrospective CT/MR volumetric analysis of 20 GLP-1RA-treated patients, each 10-kg reduction in body weight was associated with an estimated 7% reduction in midfacial volume; median total midfacial volume reduction was 9% (IQR, 3–14%), with greater loss in superficial than deep fat compartments.⁸ Although facial changes after massive weight loss have also been described in bariatric surgery cohorts, these findings provide only contextual support because the mechanism, patient selection, and metabolic milieu may differ from medication-driven weight loss.^9,10

The biological mechanisms underlying GLP-1RA-FAA remain incompletely characterized. Experimental and review literature has proposed that GLP-1 signaling may influence adipose-derived stromal/stem-cell biology, dermal repair, and adipose–fibroblast interactions. However, GLP-1R expression and the net effects of GLP-1RA exposure on ADSCs and fibroblasts have not been established in human facial tissue and may vary across experimental models.^5,11,12 In addition, reduced estrogen signaling is associated with decreased dermal collagen synthesis in postmenopausal skin; whether GLP-1RA-associated changes in facial adipose tissue or dWAT materially alter local estrogen availability and fibroblast collagen production is speculative.^11,12 Across GLP-1RA weight-loss studies, lean-mass reductions constitute a variable but clinically relevant proportion of total weight loss, commonly estimated at approximately 25–40% in reviews. Whether these systemic changes extend to facial mimetic or elevator muscles has not been directly investigated.^4,13

On October 15, 2025, the US Food and Drug Administration issued a Safety Communication regarding serious complications reported with certain uses of radiofrequency microneedling devices for dermatologic or aesthetic procedures, including burns, scarring, fat loss, disfigurement, and nerve damage.¹⁴ This signal reinforces the importance of establishing tissue-specific safety margins when considering energy-based device treatment in volume-depleted facial anatomy.

Scope and limitations: This narrative review examines principal EBD classes and develops a conceptual, safety-oriented framework for GLP-1RA-FAA. As of the literature-search cutoff, direct clinical evidence for EBD use in GLP-1RA-FAA was limited to one uncontrolled case series of subdermal bipolar RF; recommendations for other EBD categories are extrapolated from general facial-aging cohorts, massive-weight-loss populations, body-contouring studies, and preclinical mechanistic literature. All therapeutic considerations are hypothesis generating and should not be interpreted as validated clinical guidelines or standards of care. Devices are categorized according to physical energy-delivery principles. Commercial names are used only at first mention to identify the studied platform and do not imply endorsement or comparative superiority. The aim is to provide a tissue-specific safety analysis and identify priorities for prospective clinical investigation.

Materials and Methods

This expert-authored narrative review synthesized mechanistic, preclinical, and clinical literature to develop a hypothesis-generating, safety-oriented framework for the consideration of energy-based devices (EBDs) in GLP-1 receptor agonist–associated facial accelerated aging (GLP-1RA-FAA). The review was not designed or reported as a systematic review or formal scoping review; accordingly, PRISMA reporting standards were not applied. PROSPERO registration was not undertaken because the work was designed as a narrative review rather than a systematic review. Structured searches of PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library were conducted from January 1, 2000, through August 31, 2026. Search strategies combined controlled vocabulary, where available (MeSH for PubMed/MEDLINE and Emtree for Embase), with free-text terms across four conceptual domains: (1) GLP-1 receptor agonists and medication-driven weight loss; (2) facial aging, facial volume loss, and dermal–subcutaneous tissue changes; (3) energy-based devices; and (4) tissue-specific mechanisms, including adipocyte injury or preservation, fibroblast–extracellular-matrix remodeling, wound-healing responses, and facial muscle–SMAS structure. Representative database-specific search strategies are provided in Supplementary Appendix S1. Sources considered eligible for inclusion comprised English-language peer-reviewed original research, including relevant preclinical in vitro and in vivo studies; clinical studies and case series; systematic reviews; and expert consensus statements. Relevant regulatory safety communications were reviewed for safety context. Conference abstracts, non-peer-reviewed commentaries, duplicate reports, and sources without sufficient methodological information were excluded. Body-contouring-only studies were not considered direct clinical evidence for GLP-1RA-FAA; however, studies of nonfacial adipose tissue were retained when they provided mechanistic or safety-relevant information regarding energy distribution, adipocyte thermal injury, apoptosis, or tissue-depth effects. Literature selection and qualitative synthesis were guided by clinical directness to GLP-1RA-FAA, thematic relevance to the proposed adipocyte–fibroblast/ECM–muscle/SMAS framework, study design, relevance to volume-depleted facial anatomy, and applicability to device-related safety. As expected for an expert-authored narrative review, selection did not involve dual-independent screening, formal inclusion/exclusion adjudication, or risk-of-bias assessment. Consequently, the search and selection process is less reproducible and more susceptible to selection bias than a systematic review. An exception to the prespecified date range was made for a seminal 1954 biophysical text describing foundational electromagnetic tissue properties. Manufacturer technical documentation was used solely to verify device-specific physical characteristics, such as nominal frequency, handpiece configuration, treatment depth, and cooling architecture; it was explicitly identified in the text and was not used as efficacy evidence. For each device-specific finding, the source population—GLP-1RA-FAA patients, general facial-aging cohorts, massive-weight-loss cohorts, or animal/in vitro models—and study design are described to facilitate assessment of evidentiary strength and applicability. Evidence classification is summarized in Supplementary Table S1.

Pathophysiology of GLP-1RA-FAA: A Three-Target Model

The proposed three-target pathophysiology model, integrating changes in the adipocyte compartment, fibroblast function, and facial muscle–SMAS support, is summarized in Table 1.

Table 1.

Pathophysiology of GLP-1RA-FAA: A Three-Target Model

Tissue Target	Hypothesized/Extrapolated Mechanism	Clinical Phenotype	Evidence Tier
Adipocyte	GLP-1R–mediated ADSC suppression (glucose/ATP reduction)	Imaging-observed midfacial volume reduction, greater superficially than deeply; possible adipose/ADSC-related mechanisms remain unconfirmed.	Tier B & C (clinical and preclinical)
Fibroblast	Integrin–FAK and YAP/TAZ mechanical collapse → metabolic quiescence	Possible loss of dermal–subcutaneous mechanical support with extrapolated mechanotransduction changes; not demonstrated in GLP-1RA-treated facial tissue.	Tier C & D (preclinical and theoretical)
Muscle–SMAS	Systemic catabolic signaling → structural protein insufficiency	Possible relevance of systemic lean-mass loss to facial muscle and soft-tissue support; facial muscle and SMAS effects are unmeasured and hypothetical.	Tier B & D (clinical and theoretical)

Adipocyte Compartment

Facial fat is organized into superficial and deep compartments.¹⁵ In a retrospective CT/MR cohort of 20 GLP-1RA-treated patients, midfacial volume loss was greater in superficial than in deep compartments, and weight loss correlated with superficial, but not deep, volume reduction. This imaging observation does not establish selective adipocyte depletion or compartment-specific histologic change in GLP-1RA-treated facial tissue.⁸ Experimental studies indicate that GLP-1/GLP-1R signaling can influence preadipocyte proliferation, survival, and differentiation, but the direction and relevance of these effects appear model dependent. In 3T3-L1 and murine preadipocyte models, GLP-1 and liraglutide promoted proliferation and adipogenesis while reducing apoptosis; whether chronic pharmacologic GLP-1RA exposure alters glucose handling, ATP availability, survival, or differentiation of human facial ADSCs remains unknown.¹¹ In peri- and postmenopausal skin, reduced estrogen signaling is associated with reduced dermal fibroblast activity, collagen synthesis, and skin thickness. Whether GLP-1RA-associated alterations in facial adipose tissue or dWAT reduce local estrogen availability sufficiently to impair fibroblast collagen production is speculative and has not been demonstrated in human facial tissue.¹¹

Fibroblast Compartment

In aged skin, loss of dermal extracellular-matrix support and mechanical tension can impair fibroblast spreading and elongation, with altered integrin–FAK and YAP/TAZ signaling implicated in this process.^16,17 These changes may be accompanied by reduced fibroblast function and increased matrix metalloproteinase activity, contributing to extracellular-matrix degradation.¹⁸ Whether rapid GLP-1RA-associated facial volume loss induces the same mechanobiologic sequence remains unknown.

Muscle–SMAS Compartment

In the absence of direct facial muscle data in GLP-1RA-treated patients, any muscle-related interpretation is extrapolated from systemic body-composition studies. Facial expression and mastication involve multiple anatomically and functionally distinct muscle groups, and it remains unknown whether systemic lean-mass loss affects facial mimetic or elevator muscles proportionally. Craniofacial and appendicular muscles arise through distinct developmental programs: facial expression muscles derive predominantly from cranial paraxial mesoderm associated with the second pharyngeal arch, whereas appendicular skeletal muscles derive from somite-derived paraxial mesoderm. Cranial neural crest contributes principally to craniofacial skeletal and connective tissues rather than the muscle fibers themselves. These developmental and functional differences may influence fiber composition, regenerative biology, and metabolic responses, but their relevance to GLP-1RA-associated muscle loss is unestablished.^4,13 A proposed model is that loss of facial muscle bulk or tone could reduce upward soft-tissue support, while reduced dermal–subcutaneous support could contribute to altered SMAS-related tension; these relationships remain hypothetical and are illustrated conceptually in Figure 1A.

Figure 1.

Proposed three-target model and nominal depth of energy delivery in GLP-1RA-associated facial accelerated aging (GLP-1RA-FAA). (A) Proposed tissue-level targets in GLP-1RA-FAA: dermal fibroblast mechanical-tension collapse, subcutaneous adipocyte volume loss (greater in superficial than deep compartments), and hypothesized reduction in SMAS support and facial-muscle mass. Layer relationships, including superficial and deep fat compartments, retaining ligaments, SMAS/fascial planes, and mimetic muscles, vary substantially by facial region; the diagram is intended only as a conceptual depth-oriented framework. (B) Nominal device/transducer depth ranges and conceptual—not comparative—considerations in volume-depleted facial anatomy. The shaded superficial zone is conceptual and has no validated cutoff. Risk categories are theoretical and reflect potential concern related to deeper energy deposition; they do not represent comparative clinical safety or efficacy. The schematic is not to scale, and tissue-layer thickness varies by facial region and may be reduced in volume-depleted faces.

Abbreviations: BBL/NIR, broadband light/near-infrared; EBD, energy-based device; GLP-1RA-FAA, glucagon-like peptide-1 receptor agonist–associated facial accelerated aging; HIFES, high-intensity facial electrical stimulation; HIFU, high-intensity focused ultrasound; MMP, matrix metalloproteinase; RF, radiofrequency; SMAS, superficial musculoaponeurotic system.

The Thermal Remodeling Paradox in GLP-1RA-FAA

A central biological uncertainty underlies the use of thermal energy-based devices (EBDs) in GLP-1RA-associated facial accelerated aging. Many thermal EBDs are intended to induce controlled collagen denaturation or focal thermal injury, followed by inflammatory signaling, extracellular-matrix turnover, fibroblast-mediated remodeling, and neocollagenesis.¹⁹ Whether the same reparative response occurs in GLP-1RA-associated facial volume loss is unknown. Tissue-repair capacity may be influenced by nutritional status,²⁰ vascular supply, hormonal milieu, extracellular-matrix integrity, and local cell-mediated signaling; however, these variables have not been characterized in GLP-1RA-treated facial tissue. The net effects of GLP-1RA exposure on adipose-derived stromal/stem-cell survival and adipogenesis, as well as on fibroblast function, oxidative stress, and collagen-related repair, remain incompletely characterized and may be context dependent.^5,11 Loss of dermal–subcutaneous mechanical support after facial volume reduction may provide a plausible mechanobiologic mechanism for altered fibroblast behavior. In chronologically aged skin, collagen fragmentation and loss of matrix support reduce fibroblast spreading and mechanical tension, contributing to impaired matrix synthesis and extracellular-matrix degradation. Altered mechanotransduction, including YAP/TAZ signaling, has been implicated in this process.^16–18 During ongoing rapid weight loss or inadequate energy and protein intake, reduced substrate availability may further influence tissue-repair capacity; this consideration is extrapolated from general nutrition and sarcopenia literature rather than directly tested in GLP-1RA-associated facial aging.^4,13 Accordingly, it is not known whether thermal stimulation in GLP-1RA-associated facial aging produces the intended regenerative remodeling response, an attenuated response, or a less favorable pattern of matrix remodeling. The possibility of maladaptive fibrosis is theoretical and has not been evaluated directly. This uncertainty applies to thermal EBD modalities and represents a central gap in the rationale for EBD application to GLP-1RA-FAA. Until dedicated studies compare fibroblast wound-healing and extracellular-matrix responses after thermal stimulation in GLP-1RA-treated versus matched non-GLP-1RA facial tissue, all device-related considerations should be interpreted as hypothesis generating rather than as validated clinical guidance.

Device-Specific Tissue Interactions

The following analysis categorizes EBDs by their physical energy delivery principles rather than commercial designations. Where specific platforms have been studied in peer-reviewed literature, they are identified at first mention; subsequent references use generic modality terms. All clinical extrapolations to GLP-1RA-FAA patients are clearly delineated, and the absence of direct evidence for most modalities is emphasized throughout (Figure 1B and Table 2).

Table 2.

Comparative EBD Framework for GLP-1RA-FAA: Non-Validated, Hypothesis-Generating Research Considerations

Modality	Target Depth	Adipocyte Risk	Potential Research Consideration; not a Clinical Protocol
Monopolar RF (6.78 MHz)	≤20 mm	HIGH	Substantial energy reduction (proposed); avoid bony prominences
Transcutaneous Bipolar RF	1–4 mm	LOW	Proposed for volume-depleted zones (distinct from subdermal RF)
Fractional RF Microneedling	0.5–8 mm	MOD–HIGH	Minimize depth per anatomical zone; reduce fluence
Low-Freq Bipolar RF	Dermis–subcutis	LOW	dWAT-targeted; requires validation
Dielectric RF (40.68 MHz)	Variable	MODERATE	Superficial config for midface
Microwave (2.45 GHz)	3–12 mm	HIGH (deep)	3 mm handpiece only
BBL/NIR	Epi–upper dermis	LOW	May be considered for study as a relatively superficial dermal-targeting approach
Diode Laser (755/810/1064)	Deep dermis	MODERATE	Superficial continuous-motion for midface
HIFU 1.5 mm	1.5 mm	LOW	May be evaluated as a shallower focal-depth option
HIFU 3.0 mm	3.0 mm	LOW–MOD	Second-choice transducer; preferred over 4.5 mm
HIFU 4.5 mm	4.5 mm	HIGH	Avoidance of unnecessary deep focal heating may be considered in volume-depleted regions
ESWT	Variable	LOW (low EFD)	No validated facial EFD threshold; low-EFD ranges used in selected experimental studies should not be interpreted as a clinical cutoff
Synch. RF+HIFES	Dermis+muscle	LOW	Stabilization phase General sarcopenia guidance (protein intake)

Notes: (All entries are non-validated, hypothesis-generating research considerations. They are not device-specific treatment recommendations, safety thresholds, or standards of care for GLP-1RA-treated patients).

Impedance-Based Monopolar Radiofrequency (6.78 MHz)

Monopolar radiofrequency (RF) platforms commonly operating at 6.78 MHz deliver current from an active treatment electrode through tissue to a dispersive return electrode, producing resistive heating within cutaneous and subcutaneous tissues. The heating pattern is influenced by device configuration, tissue impedance, cooling strategy, local tissue composition, and perfusion rather than by frequency alone. Computational studies suggest that fibrous septa within subcutaneous tissue can alter local RF current density and heating relative to adjacent fat lobules, potentially contributing to dermal and septal collagen remodeling.²¹ Current flows preferentially through low-impedance fibroseptal networks, producing horizontal dermal and vertical septum contraction.²² Collagen denaturation and immediate fibril contraction may occur at target-tissue temperatures in the approximate 60–65°C range, depending on exposure duration. Subsequent extracellular-matrix remodeling and neocollagenesis may evolve over several months, although their timing and magnitude vary across devices and treatment protocols.^21,22

Adipocyte Risk

Thermal adipocyte injury is time- and temperature-dependent. In experimental studies, exposure to 45°C for approximately 3 minutes reduced adipocyte viability in vitro, whereas sustained exposure in the approximate 43–45°C range for 15 minutes was associated with delayed adipocyte cell death in porcine subcutaneous fat.²³ In a separate porcine focused-monopolar RF model (n=3), TUNEL-positive adipocyte apoptotic indices ranged from 39.6% to 53.4% after treatment, compared with 7% at baseline; variability estimates and formal comparative statistical testing were not reported.²⁴ These body-contouring and porcine findings should not be interpreted as a validated temperature threshold for facial tissue, but they provide a precautionary signal that deep or prolonged subcutaneous heating may increase adipocyte-injury risk.^23,24 In selected facial regions over bony prominences, the combined thickness of skin and superficial soft tissue may be only a few millimeters. In patients with clinically apparent facial volume loss after medication-driven weight loss, residual soft-tissue thickness may be limited and anatomically variable.^8,9 Consequently, conservative, anatomy-informed parameter selection is a hypothesis-based safety consideration rather than a validated GLP-1RA-FAA protocol.

Commercial monopolar RF platforms differ in electrode geometry, impedance feedback, cooling strategy, and treatment algorithms, each of which can influence energy distribution and tolerability.^22,25 Whether fibroblasts in GLP-1RA-associated facial volume loss exhibit an altered response to thermal stimulation or can mount a neocollagenesis response comparable to that observed in general aging skin remains unknown.^5,11,16–18

Bipolar Radiofrequency

Bipolar RF configurations confine current flow predominantly between adjacent electrodes, producing a more localized energy field than monopolar RF. The effective depth and thermal distribution depend on interelectrode distance, electrode geometry, tissue impedance, power, pulse duration, contact, and cooling; therefore, a fixed 1–4 mm penetration range should not be generalized across bipolar RF platforms. Compared with monopolar systems, superficial transcutaneous bipolar configurations may reduce—but do not eliminate—the likelihood of energy deposition in deep subcutaneous tissue.

Subdermal bipolar RF (BodyTite; InMode, Yokneam, Israel). As of the literature-search cutoff, one uncontrolled case series directly enrolled patients described as having GLP-1RA-associated facial changes. In 24 participants treated with subdermal bipolar RF, clinical improvement was reported through a minimum follow-up of 12 months, with transient erythema and no reported serious adverse events.²⁶ The study reported patient satisfaction and independent expert assessment, but lacked a control group, randomization, objective fat-compartment imaging, tissue histology, and a multicenter design. Its findings should therefore be interpreted as preliminary direct clinical evidence requiring controlled replication.²⁶

Fractional Radiofrequency Microneedling

Fractional RF microneedling combines physical micro-injury with RF energy at the needle tip. Multiple platforms exist with distinct RF polarity (monopolar vs bipolar), needle configurations, and depth ranges.²⁷

FDA Safety Communication (October 15, 2025). The FDA issued a Safety Communication regarding serious complications reported with certain uses of RF microneedling devices for dermatologic or aesthetic procedures, including burns, scarring, fat loss, disfigurement, and nerve damage.¹⁴ Whether GLP-1RA-associated facial volume loss increases the frequency or severity of these adverse outcomes remains unknown. In volume-depleted facial regions, diminished distance between the skin surface, subcutaneous tissue, periosteum, and adjacent neurovascular structures may theoretically reduce the margin for error during deep needle-based energy delivery. However, no study has demonstrated impedance spikes, marginal mandibular nerve injury, or a validated needle-depth threshold specifically in GLP-1RA-FAA. A clinically relevant distinction exists between RF microneedling systems designed to treat the upper/mid dermis and those capable of deeper needle insertion. Deeper settings may reach subcutaneous tissue, depending on patient anatomy and device configuration.²⁷

Newer platforms incorporating real-time impedance calibration or hybrid non-invasive/invasive RF architectures have been introduced,²⁸ but peer-reviewed clinical data in GLP-1RA-FAA patients remain unavailable for all platforms. Conservative, anatomy-informed treatment planning is therefore hypothesis generating rather than validated clinical guidance.

Low-Frequency Bipolar RF (0.5 MHz)

Manufacturer-supported mechanistic models suggest a dual modulation: rapid hyaluronan production for tissue turgor and slower dWAT preadipocyte differentiation.²⁹ If validated in independent studies, this mechanism may support dWAT-related remodeling; however, peer-reviewed human outcome data remain limited, and the proposed etiological dWAT restoration mechanism has not been confirmed in GLP-1RA-FAA patients. The proposed mechanism exploits the conductivity differential between intracellular triglyceride and pericellular ECM to generate micro-scale temperature gradients without thermal destruction.³⁰

RF-associated increases in hyaluronan have been reported in studies of fractional microneedle RF,³⁰ but this cannot be assumed to establish rapid hyaluronan synthesis or dWAT preadipocyte differentiation after noninvasive 0.5-MHz bipolar RF. Although GLP-1RA-associated facial aging has been hypothesized to involve changes in facial adipose tissue, dWAT, ADSCs, fibroblast activity, and collagen homeostasis,³¹ the available literature remains predominantly mechanistic and review-based. No independent human clinical or histologic study was identified demonstrating restoration of dWAT, induction of dWAT adipogenesis, or reversal of GLP-1RA-associated facial aging by low-frequency bipolar RF.

High-Frequency Dielectric Radiofrequency (40.68 MHz)

In a hairless-mouse model, repeated treatment with a 40.68-MHz electrical-field RF device induced epidermal hyperplasia, increased collagen staining, increased collagen type I, TGF-β, and VEGF mRNA expression, and subcutaneous fat atrophy.³² The study did not report TUNEL-based confirmation of adipocyte apoptosis; thus, fat atrophy should not be equated with apoptosis in this model. Separate high-frequency focused-field RF biopsy studies have reported increased TUNEL-positive adipocyte apoptosis after protocols producing sustained subcutaneous temperatures near 45°C,³³ but these findings cannot be directly extrapolated to 40.68-MHz facial RF treatment.

Clinical RF protocols can intentionally reduce submental adipose thickness,³⁴ but the risk of unintended facial fat loss after high-frequency RF, the relevant energy-dose threshold, and compartment-specific susceptibility remain incompletely characterized. In patients with GLP-1RA-associated facial volume loss, selection of superficial dermal-targeting settings in vulnerable midfacial and periorbital regions, while avoiding unnecessary deep subcutaneous heating except where fat reduction is intended, should be described as a precautionary clinical approach rather than an evidence-based protocol. Prospective validation using objective compartmental imaging and long-term follow-up is required.

Microwave Thermotherapy (2.45 GHz)

A 2.45-GHz microwave platform has been designed to preferentially deposit energy in the subdermal compartment through the combined effects of operating frequency, coaxial applicator geometry, tissue coupling, and contact cooling. Device-associated materials describe a greater fraction of deposited energy in subcutaneous fat than in the dermis; however, quantitative adipocyte-versus-dermis absorption fractions have not been independently validated across tissue compositions and handpiece configurations.³⁵ For newer platform generations that include a nominal 3-mm facial applicator, use of a superficial facial handpiece may be a manufacturer-defined option. In GLP-1RA-associated facial volume loss, limiting microwave treatment to superficial facial configurations and avoiding deep subcutaneous applicators is a precautionary, anatomy-based consideration rather than a prospectively validated protocol. Direct studies using facial ultrasound, MRI, or 3D volumetric imaging are needed to define safety margins and tissue-specific effects.

Broadband Light and Near-Infrared (BBL/NIR)

Broadband infrared platforms spanning approximately 800–1400 nm are designed to produce nonablative bulk dermal heating through absorption by water-containing tissue components, with epidermal cooling intended to protect the skin surface. The effective heating profile, however, is device- and parameter-dependent rather than determined by wavelength range alone. In a small pilot study of five women with photodamaged forearm skin, Chang et al identified 2265 coding and noncoding RNAs that differed between young and aged skin; after three BBL treatments, 1293 transcripts shifted toward an expression profile more similar to young skin.³⁶ This transcriptomic finding has not been replicated in facial skin, dWAT, or GLP-1RA-associated facial aging. Whether such molecular changes translate into a clinically relevant effect within the altered dermal–adipose microenvironment of GLP-1RA-FAA remains unknown. With conservative dermal-targeting settings, deeper adipose exposure may be limited in principle, but direct evidence of facial adipocyte or dWAT preservation is lacking.

Three-Wavelength Diode Laser (755/810/1064 nm)

Simultaneous irradiation with 755, approximately 810, and 1064 nm has been investigated as a nonablative strategy to distribute photothermal effects across multiple dermal depths. In ex vivo porcine skin, thermal-damage depth increased with wavelength, and the triple-wavelength configuration produced a depth profile comparable to 1064 nm irradiation; in guinea pigs, it increased epidermal thickness and dermal collagen density relative to 1064 nm alone.³⁷ The 1064 nm wavelength can penetrate more deeply than shorter near-infrared wavelengths. In abdominal body-contouring studies, 1060/1064 nm diode-laser protocols designed to maintain subcutaneous hyperthermia in the approximate 42–47°C range have been associated with delayed adipocyte injury and TUNEL-positive apoptosis.³⁸ These data cannot be used to infer an adipocyte-apoptosis threshold above 47°C, nor can they be directly extrapolated to facial fat compartments, where tissue thickness, perfusion, facial anatomy, eye proximity, and desired clinical endpoints differ substantially. In GLP-1RA-associated facial volume loss, preference for conservative superficial moving techniques in volume-deficient midface and periorbital regions, with avoidance of high-energy static or stacked delivery outside areas where fat reduction is intended, remains a precautionary clinical concept rather than an evidence-based protocol.

High-Intensity Focused Ultrasound

MFU-V (microfocused ultrasound with visualization) generates discrete thermal coagulation points (TCPs) at transducer-defined focal depths; histologic studies have demonstrated focal TCPs corresponding to 1.5-, 3.0-, and 4.5-mm transducer depths. Real-time ultrasound visualization can facilitate confirmation of the intended tissue plane and adequate transducer–skin coupling, enabling adjustment of focal depth and avoidance of non-target structures. Because 4.5-mm transducers may target superficial subcutaneous or fibromuscular/SMAS-related planes, inappropriate depth selection, excessive line density, overlap, or blind treatment could plausibly increase the risk of unintended soft-tissue injury in thin or volume-depleted faces. This risk is supported mainly by complication reports and expert consensus rather than by prospective dose–response studies. The incidence and energy-dose threshold for MFU-associated facial fat atrophy remain undefined. In a small uncontrolled clinical study using 3.0- and 4.5-mm transducers, no clinically apparent fat atrophy was reported through 6 months; however, objective fat-compartment imaging was not performed.³⁹

In GLP-1RA-associated facial volume loss, preferential use of 1.5- or 3.0-mm transducers, reduced energy density, and real-time tissue visualization may be considered a precautionary anatomy-based strategy to avoid unnecessary deep focal heating. This approach is not yet a validated GLP-1RA-FAA-specific protocol and requires prospective imaging-based evaluation.

Low-energy HIFU has been reported to induce an adipogenesis-associated molecular pattern in healthy rat subcutaneous white adipose tissue.⁴⁰ In a 0.2-J, 7-MHz, 2-mm focal-depth rat model, HIFU increased HSP70, reduced NF-κB, IL-6, and TNF-α, decreased cilia-disassembly factors, increased cilia-assembly factors and primary-cilium length, reduced WNT5A/β-catenin, increased PPARγ and C/EBPα, and increased adipocyte number and sWAT thickness. A subsequent small swine facial study reported similar changes in HSP70, NF-κB, AURKA, ARL13B, WNT5A, CTNNB1, PPARG, and CEBPA, accompanied by increased facial subcutaneous thickness and MRI-assessed fat volume, most prominently near the zygomatic arch.⁴¹ However, both studies were preclinical, involved healthy tissue, had manufacturer-associated support, and did not model GLP-1RA exposure, rapid weight loss, or human facial volume depletion. They therefore cannot establish adipogenic restoration in GLP-1RA-associated facial aging.

Although energy-based modalities and biostimulatory injectables are often combined, robust evidence defining whether HIFU should precede a specific biostimulator, at what interval, and with what incremental regenerative benefit remains limited.

Extracorporeal Shock Wave Therapy

ESWT delivers high-amplitude acoustic pressure waves that can generate cavitation and mechanical stress, thereby initiating mechanotransduction.⁴² Pathways potentially involved include integrin-associated signaling, MAPK/ERK activation, and other mechanosensitive effectors such as Piezo channels and YAP/TAZ; however, the specific pathway hierarchy in facial adipose tissue has not been established. Facial acoustic-wave therapy has shown clinical tightening effects in a large observational cohort using focused and radial waves, including focused-wave settings nominally reported at 0.45–0.88 mJ/mm².⁴³

Experimental studies suggest that low-energy ESWT, often in the approximate 0.09–0.13 mJ/mm² range, can enhance adipose-derived stromal/stem-cell viability, ATP content, and adipogenic differentiation potential under selected in vitro or ex vivo conditions.^44,45 In contrast, higher shockwave doses may produce cellular injury or apoptosis in experimental systems,⁴⁶ but no validated EFD threshold—such as 0.20 mJ/mm²—has been established for adipocyte apoptosis in facial tissue. Cellulite protocols have used focused ESWT in the 0.25–0.35 mJ/mm² range, but clinical cellulite outcomes do not by themselves demonstrate adipocyte apoptosis.

Synchronized Radiofrequency with High-Intensity Facial Electrical Stimulation

Synchronized RF plus high-intensity facial electrical stimulation is designed to combine dermal heating with electrically induced facial-muscle contractions.⁴⁷ In an industry-funded porcine histology study, four 20-minute treatments were associated with a 19.2% increase in facial muscle mass density at 2 months, (p < 0.001), a 21.2% increase in myonuclei (p < 0.01), and an increase in muscle-fiber count from 56.8 ± 7.1 to 68.0 ± 8.6 (p < 0.001).⁴⁸ Although the original report provided selected variability data and formal statistical testing, its small active group (n=6), extremely small untreated control group (n=2), absence of sham treatment, industry funding, and lack of independent replication make the findings preliminary.

Published human studies have reported facial lifting, skin-quality improvement, and muscle-related outcomes after synchronized RF plus HIFES;^49,50 however, independent, adequately powered, sham-controlled trials using standardized muscle imaging and long-term follow-up remain necessary to confirm clinically meaningful facial-muscle hypertrophy.

The muscle-targeting capability is theoretically relevant to GLP-1RA-FAA, where systemic lean mass loss of 20–50% of total weight lost has been reported,⁵¹ though facial muscle-specific data remain unavailable. Notably, in a retrospective cohort of older adults with type 2 diabetes (semaglutide n = 220 vs controls n = 212), significant reductions in appendicular skeletal muscle mass index and gait speed over 24 months were reported,¹³ with sex-specific grip strength patterns (initial improvement followed by decline in men; continuous decline in women)—providing evidence of GLP-1RA–accelerated sarcopenia, although these findings derive from an elderly diabetic cohort and may not be directly generalizable to the broader GLP-1RA-FAA population.^4,13

Across GLP-1RA weight-loss studies, reductions in lean mass constitute a variable but clinically relevant proportion of total weight loss, commonly summarized in reviews as approximately 25–40%, although estimates vary substantially by trial, population, body-composition method, and co-interventions. In people at risk of sarcopenia, ESPEN Expert Group guidance supports protein intakes of approximately 1.2–1.5 g/kg.⁵²

Comparative Device Framework

Sex-related differences in facial fat distribution, dermal thickness, muscle mass, and skeletal morphology may plausibly influence presentation and treatment goals after GLP-1RA-associated weight loss. However, no prospective GLP-1RA-FAA study has established sex-specific facial phenotypes or demonstrated superior outcomes of broadband light, biostimulatory injectables, or muscle-targeting devices in women versus men. Any sex-stratified treatment selection should therefore be individualized and considered hypothesis-generating rather than evidence based. These proposed distinctions require prospective validation.

Theoretical Scenarios for Future Research Design

The 2025 International Multidisciplinary Delphi Consensus on medication-driven weight loss represents structured expert opinion rather than prospective empirical evidence.⁵³ Using a three-round modified Delphi process involving 10 international experts, the panel identified skin and superficial/deep facial fat pads as key tissue layers affected by medication-driven weight loss and emphasized individualized assessment according to age, sex, rate and extent of weight loss, and aesthetic goals. Seven of 10 panelists favored beginning PLLA-SCA biostimulator treatment concurrently with active weight loss; however, this statement reflects expert opinion and does not demonstrate that early treatment prevents facial deflation, improves long-term outcomes, or is superior to treatment after weight stabilization. The consensus focuses predominantly on injectables and volumization strategies. Although energy-based devices are mentioned as possible nonsurgical modalities, the document does not provide validated device-specific parameters, safety thresholds, or GLP-1RA-FAA-specific EBD treatment algorithms.

Active Weight Loss Phase

Conservative, superficial skin-directed interventions may be considered as conceptual research approaches during active medication-driven weight loss; however, no GLP-1RA-FAA-specific study has established the optimal modality, energy setting, treatment depth, interval, or safety margin. Biostimulatory injectable treatment may be considered during active weight loss according to Delphi expert opinion, rather than controlled evidence for scaffold formation or optimal timing.⁵³ Thermal energy from certain EBDs may affect HA filler integrity when energy is delivered at or near the filler plane. Immediate monopolar RF after HA filler injection has been associated with filler loss, whereas delaying RF for at least 14 days reduced this effect in a randomized study.⁵⁴

Stabilization Phase (3–6 Months Post-Target Weight)

The proposed principle of volumization preceding aggressive tightening is supported by the Delphi consensus.⁵³ Biostimulators establish a dermal scaffold; EBD tightening may then be applied to the pre-conditioned tissue.

Maintenance Phase (≥6 Months Stable Weight)

More definitive volumization or tightening may be reassessed after weight trajectory, nutritional status, and facial volume change have stabilized, but a fixed 3–6-month post-target-weight threshold has not been validated. Conservative, compartment-specific correction of persistent deficits may reduce the need for high-volume filler treatment. The proposition that EBD-mediated scaffold restoration should routinely precede injectable volumization is hypothesis generating and requires prospective controlled validation. Surgical timing and perioperative GLP-1RA management should be addressed separately using current anesthesia and surgical guidance.

Limitations

This narrative review did not use dual-independent screening or formal inclusion/exclusion adjudication; consequently, its study-selection process is less reproducible and more susceptible to selection bias than a systematic review. Meta-analysis was not undertaken because of substantial heterogeneity in device types, treatment parameters, anatomical targets, study designs, outcomes, and patient populations. As of the literature-search cutoff, direct EBD evidence in GLP-1RA-associated facial aging was limited to one uncontrolled 24-patient subdermal bipolar RF case series with a minimum 12-month follow-up;²⁶ all other device-specific recommendations were extrapolated from general-aging, body-contouring, or preclinical studies.

Conclusions

GLP-1RA-associated facial aging is best regarded as a multifactorial phenotype involving established loss of facial adipose volume and hypothesized alterations in dermal–adipose support, ADSC biology, fibroblast–ECM homeostasis, and possibly facial muscle. Early human tissue data demonstrate reduced ADSC density in GLP-1RA users, but direct evidence of altered facial fibroblast populations, impaired thermal wound-healing responses, or facial-muscle sarcopenia remains limited. No single energy-based modality has demonstrated, in prospective GLP-1RA-specific trials, simultaneous restoration of adipose/ADSC, dermal fibroblast–ECM, and facial-muscle targets. Current device recommendations are therefore largely extrapolated from general-aging, body-contouring, and preclinical literature.

Three conceptual principles emerge from this synthesis: (1) conservative energy depth control to mitigate iatrogenic fat loss; (2) cumulative low-energy strategies for potential fibroblast reactivation, acknowledging the unresolved paradox of stimulating metabolically suppressed cells; and (3) integration of muscle-targeting modalities for sarcopenia compensation. A phased multimodal approach is proposed but remains hypothesis-generating. All recommendations require prospective clinical validation in GLP-1RA-treated populations before adoption as standard of care. Future controlled studies should enroll well-characterized GLP-1RA-treated patients, use standardized three-dimensional facial imaging and high-frequency ultrasound or MRI-based soft-tissue measurements, prespecify fat-loss and safety endpoints, and follow participants for at least 12 months. Tissue studies should compare adipocyte distribution and fibroblast wound-healing responses after thermal stimulation between GLP-1RA-treated and matched chronologically aged individuals. Head-to-head trials of EBD–biostimulator sequencing are needed before an optimal multimodal approach can be established.

Funding Statement

The authors report no funding associated with this work.

Abbreviations

ADSC, adipose-derived stem cell; dWAT, dermal white adipose tissue; EBD, energy-based device; ECM, extracellular matrix; EFD, energy flux density; ESWT, extracorporeal shock wave therapy; FAA, facial accelerated aging; FDA, United States Food and Drug Administration; GLP-1RA, glucagon-like peptide-1 receptor agonist; HA, hyaluronic acid; HIFU, high-intensity focused ultrasound; HSP, heat shock protein; MFU, microfocused ultrasound; MMP, matrix metalloproteinase; NIR, near-infrared; RF, radiofrequency; SMAS, superficial musculoaponeurotic system.

Data Sharing Statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

Ethics Approval and Informed Consent

Not applicable. This article is a narrative review of existing literature and does not involve human or animal subjects.

Consent for Publication

Not applicable. This manuscript is a narrative review and does not contain any individual person’s identifiable data, images, or videos.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.